Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program [Yahoo! Finance]
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: Yahoo! Finance
Traumatic brain injuries affect more Americans each year than stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and ALS combined Sarasota, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced it has engaged DUCK FLATS Pharma as its U.S. Investigational New Drug (IND) readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its novel intranasal concussion therapy toward U.S.-based development. The engagement is intended to align the Company's upcoming Phase 2a clinical trial in Australia with its U.S regulatory strategy. “We highly value our collaboration with DUCK FLATS Pharma as we advance our IND strategy for ONP-002 and prepare for future U.S. clinical development,” said Janet Huffman, Chief Executive Officer of Orageni
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion ProgramGlobeNewswire
- Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care [Yahoo! Finance]Yahoo! Finance
- Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient CareGlobeNewswire
- Oragenics to Present at the 2026 Sequire Investor Summit in Puerto RicoGlobeNewswire
- Oragenics Q3 2025 Shareholder UpdateBusiness Wire
OGEN
Sec Filings
- 1/22/26 - Form S-3
- 1/22/26 - Form 8-K
- 1/22/26 - Form 4/A
- OGEN's page on the SEC website